Exact Sciences (EXAS) Set to Announce Quarterly Earnings on Tuesday

Exact Sciences (NASDAQ:EXAS - Get Free Report) will be announcing its earnings results after the market closes on Tuesday, November 5th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings results on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.28. The business had revenue of $699.26 million for the quarter, compared to analysts' expectations of $690.02 million. Exact Sciences had a negative net margin of 6.70% and a negative return on equity of 4.97%. The company's revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.45) EPS. On average, analysts expect Exact Sciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Exact Sciences Stock Performance

Shares of NASDAQ:EXAS traded up $0.29 during midday trading on Tuesday, hitting $69.64. The company had a trading volume of 1,293,761 shares, compared to its average volume of 2,537,046. The company has a market cap of $12.85 billion, a price-to-earnings ratio of -52.76 and a beta of 1.27. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.17 and a quick ratio of 1.98. The company has a fifty day moving average of $66.20 and a two-hundred day moving average of $56.42. Exact Sciences has a 12-month low of $40.62 and a 12-month high of $79.62.

Insider Buying and Selling at Exact Sciences

In other news, EVP Brian Baranick sold 929 shares of the stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total transaction of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 12,758 shares in the company, valued at approximately $893,060. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.36% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on EXAS shares. Stifel Nicolaus decreased their price objective on Exact Sciences from $100.00 to $82.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. Wells Fargo & Company started coverage on shares of Exact Sciences in a report on Tuesday, August 27th. They set an "overweight" rating and a $75.00 price target on the stock. The Goldman Sachs Group dropped their price target on shares of Exact Sciences from $88.00 to $75.00 and set a "buy" rating for the company in a research report on Wednesday, July 17th. Raymond James restated a "market perform" rating on shares of Exact Sciences in a research report on Thursday, September 26th. Finally, Evercore ISI upped their target price on shares of Exact Sciences from $72.00 to $80.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, Exact Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $79.92.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.